{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:17:38Z","timestamp":1785251858925,"version":"3.55.0"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Lung cancer (LC), with non-small-cell lung cancer (NSCLC) as its predominant subtype, remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have redefined the therapeutic paradigm in advanced NSCLC, durable responses are confined to a limited subset of patients. A major clinical challenge persists: the inability to accurately predict which patients will derive meaningful benefit, which will exhibit primary resistance, and which are at risk for severe immune-related toxicities. The imperative to individualize ICI therapy necessitates robust, dynamic, and accessible biomarkers. Liquid biopsy has emerged as a transformative, minimally invasive tool that enables real-time molecular and immunologic profiling. Through analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and peripheral blood immune components, liquid biopsy offers a window into both tumor intrinsic and host-related determinants of ICI response. These biomarkers not only hold promise for identifying predictive signatures\u2014such as tumor mutational burden, neoantigen landscape, or immune activation states\u2014but also for uncovering mechanisms of acquired resistance and guiding treatment adaptation. Beyond immunotherapy, liquid biopsy plays an increasingly central role in the landscape of targeted therapies, allowing early detection of actionable driver mutations and resistance mechanisms (e.g., EGFR T790M, MET amplification, and ALK fusion variants). Importantly, serial sampling via liquid biopsy facilitates longitudinal disease monitoring and timely therapeutic intervention without the need for repeated tissue biopsies. By guiding therapy selection, monitoring response, and detecting resistance early, liquid biopsy has the potential to significantly improve outcomes in NSCLC.<\/jats:p>","DOI":"10.3390\/genes16080954","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T09:43:01Z","timestamp":1755078181000},"page":"954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1285-3812","authenticated-orcid":false,"given":"Milica","family":"Kontic","sequence":"first","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, Koste Todorovica 26, 11000 Belgrade, Serbia"},{"name":"School of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1787-1438","authenticated-orcid":false,"given":"Mihailo","family":"Stjepanovic","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, Koste Todorovica 26, 11000 Belgrade, Serbia"},{"name":"School of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-7279","authenticated-orcid":false,"given":"Filip","family":"Markovic","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, Koste Todorovica 26, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm-22-4479","article-title":"A snapshot of lung cancer: Where are we now?\u2014A narrative review","volume":"11","author":"Ibodeng","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_2","first-page":"45","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemp. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-022-01505-z","article-title":"Liquid biopsy in lung cancer: Significance in diagnostics, prediction, and treatment monitoring","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Oh, M.S., Abascal, J., Rennels, A.K., Salehi-Rad, R., Dubinett, S.M., and Liu, B. (2025). Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy. Cancers, 17.","DOI":"10.3390\/cancers17061027"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Indini, A., Rijavec, E., and Grossi, F. (2021). Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): A comprehensive review. Cancers, 13.","DOI":"10.3390\/cancers13081794"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108528","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Markovi\u0107, F., Stjepanovi\u0107, M., Samard\u017ei\u0107, N., and Konti\u0107, M. (2024). The Association of Immune-Related Adverse Events with the Efficacy of Atezolizumab in Previously Treated Advanced Non-Small-Cell Lung Cancer Patients: A Single-Center Experience. Cancers, 16.","DOI":"10.3390\/cancers16172995"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00262-019-02310-2","article-title":"Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: Insights from long-term survivors","volume":"68","author":"Nadal","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.20.01149","article-title":"Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: Final results from SWOG S1403","volume":"38","author":"Goldberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","article-title":"Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","article-title":"Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated with Worse Outcomes in Patients With EGFR-Mutant Lung Cancer","volume":"19","author":"Stockhammer","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Oya, Y., Yoshida, T., Asada, K., Oguri, T., Inui, N., Morikawa, S., Ito, K., Kimura, T., Kunii, E., and Matsui, T. (2021). Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. BMC Cancer, 21.","DOI":"10.1186\/s12885-020-07777-2"},{"key":"ref_25","first-page":"63","article-title":"Signalling pathways in cancer\u2014A report from the European Society for Medical Oncology symposium","volume":"12","author":"Kwapisz","year":"2016","journal-title":"Oncol. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Samaha, R., El Sayed, R., Alameddine, R., Florescu, M., Tehfe, M., Routy, B., Elkrief, A., Belkaid, W., Desilets, A., and Weng, X. (2025). Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study). Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020057"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.21037\/jtd.2020.01.19","article-title":"KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting","volume":"12","author":"Nacchio","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jclinpath-2020-207107","article-title":"Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: A retrospective study","volume":"75","author":"Iaccarino","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Munera-Maravilla, E., Torres-Mart\u00ednez, S., Mosqueda, M., Bell\u00f3n, M.L., Navarro, L., Espinosa-Olarte, P., Blasco-Cordellat, A., Caballero, C., Jantus-Lewintre, E., and Calabuig-Fari\u00f1as, S. (2024). Liquid biopsy for monitoring response in KRAS-mutated NSCLC patients treated with first-line immunotherapy. J. Liq. Biopsy, 5.","DOI":"10.1016\/j.jlb.2024.100186"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102631","DOI":"10.1016\/j.esmoop.2024.102631","article-title":"52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)","volume":"9","author":"Leonetti","year":"2024","journal-title":"ESMO Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1538-7445.AM2020-3385","article-title":"Abstract 3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study","volume":"80","author":"Le","year":"2020","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jtho.2020.10.033","article-title":"OFP01.01 Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1158\/1078-0432.CCR-18-4049","article-title":"Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations","volume":"25","author":"Rich","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_35","first-page":"768","article-title":"Early Blood-based Liquid Biopsy in Patients with Treatment-na\u00efve Metastatic Adenocarcinoma of the Lung: A Case Series","volume":"22","author":"Peled","year":"2020","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2019.01.009","article-title":"Molecular Analysis of Plasma from Patients with ROS1-Positive NSCLC","volume":"14","author":"Rooney","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/PO.19.00281","article-title":"Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients with Non-Small-Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","article-title":"Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types","volume":"30","author":"Kasi","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/cancers7020763","article-title":"Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer","volume":"7","author":"Isozaki","year":"2015","journal-title":"Cancers"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Markovi\u0107, F., Milin-Lazovi\u0107, J., Nikoli\u0107, N., Golubovi\u0107, A., Stjepanovi\u0107, M., and Konti\u0107, M. (2025). KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32060365"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell\u2013mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/j.cllc.2023.04.010","article-title":"Brief Report: Predictive value of PD-L1 Expression in non\u2013Small-Cell Lung Cancer-Should we Set the Bar Higher for Monotherapy?","volume":"24","author":"Nikolic","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Brun, S.S., Hansen, T.F., Wen, S.W.C., Nyhus, C.H., Bertelsen, L., Jakobsen, A., and Nederby, L. (2024). Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-59791-0"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2217\/imt-2021-0238","article-title":"Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: A meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Raza, A., Mohsen, R., Kanbour, A., Zar Gul, A.R., Philip, A., Vijayakumar, S., Hydrose, S., Prabhu, K.S., Al-Suwaidi, A.K., and Inchakalody, V.P. (2023). Serum immune mediators as novel predictors of response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1157100"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ijc.31923","article-title":"Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti\u2010PD\u20101 inhibitor","volume":"144","author":"Matsuo","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Akbar, S., Raza, A., Mohsin, R., Kanbour, A., Qadri, S., Parray, A., Zar Gul, A.R., Philip, A., Vijayakumar, S., and Merhi, M. (2023). Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1097117"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Luo, Y.-H., Yang, Y.-P., Chien, C.-S., Yarmishyn, A.A., Ishola, A.A., Chien, Y., Chen, Y.-M., Tsai, P.-H., Lin, T.-W., and Wang, M.-L. (2022). Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010064"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kokkotou, E., Grapsa, D., Papadopoulou, A., Gaitanakis, S., Bakakos, P., Poulakou, G., Moutsatsou, P., and Syrigos, K. (2025). Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. Cancers, 17.","DOI":"10.3390\/cancers17030421"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non\u2013Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3892\/ijo.2016.3616","article-title":"Neutrophils in cancer development and progression: Roles, mechanisms, and implications (Review)","volume":"49","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106677","DOI":"10.1016\/j.intimp.2020.106677","article-title":"Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"85","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.2147\/CMAR.S329963","article-title":"Dynamics of early serum tumour markers and neutrophil-to-lymphocyte ratio predict response to PD-1\/PD-L1 inhibitors in advanced non-small-cell lung cancer","volume":"13","author":"Tang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhou, K., Cao, J., Lin, H., Liang, L., Shen, Z., Wang, L., Peng, Z., and Mei, J. (2022). Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.962173"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12957-023-03077-8","article-title":"Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: A retrospective cohort study","volume":"21","author":"Zheng","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Raphael, A., Feldman, A.K., Lazarev, I., Kian, W., Peled, N., Hod, K., Shalata, W., and Dudnik, E. (2025). Lung Immune Prognostic Index-Based Predictive Score in Advanced Non-Small Cell Lung Cancer with a Programmed Death Ligand-1 Tumor Proportion Score \u2265 50%. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103543"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s12094-023-03370-8","article-title":"Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1\/PD-L1","volume":"26","author":"Shao","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: The phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhu, H., Xie, D., Yu, Y., Yao, L., Xu, B., Huang, L., Wu, S., Li, F., Zheng, Y., and Liu, X. (2021). KEAP1\/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer: Results from Two Multicenter, Randomized Clinical Trials. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.659200"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2500181","DOI":"10.1200\/PO-25-00181","article-title":"Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non\u2013Small Cell Lung Cancer (LIQUIK)","volume":"9","author":"Samol","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-20-3771","article-title":"A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study","volume":"27","author":"Si","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/07357907.2024.2316297","article-title":"NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy","volume":"42","author":"Ye","year":"2024","journal-title":"Cancer Investig."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chen, T., Wang, M., Chen, Y., Cao, Y., and Liu, Y. (2024). Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer. Cell Biosci., 14.","DOI":"10.1186\/s13578-024-01283-9"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2413125","DOI":"10.1002\/advs.202413125","article-title":"Integration of Circulating Tumor DNA and Metabolic Parameters on 18F\u2010Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non\u2010Small Cell Lung Cancer","volume":"12","author":"Wu","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Costantini, A., Kamga, P.T., Dumenil, C., Chinet, T., Emile, J.F., and Leprieur, E.G. (2019). Plasma biomarkers and immune checkpoint inhibitors in non-small cell lung cancer: New tools for better patient selection?. Cancers, 11.","DOI":"10.3390\/cancers11091269"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Heeke, S., Benzaquen, J., Long-Mira, E., Audelan, B., Lespinet, V., Bordone, O., Lalv\u00e9e, S., Zahaf, K., Poudenx, M., and Humbert, O. (2019). In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 11.","DOI":"10.3390\/cancers11091271"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"114306","DOI":"10.1016\/j.ejca.2024.114306","article-title":"Benchmarking whole exome sequencing in the German network for personalized medicine","volume":"211","author":"Menzel","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cpt.3416","article-title":"Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOOD-PAC Landscape Analysis","volume":"117","author":"Lockwood","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/2767-9764.CRC-23-0340","article-title":"Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination","volume":"3","author":"Simmons","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: State of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/8\/954\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:17Z","timestamp":1760034377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/8\/954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["genes16080954"],"URL":"https:\/\/doi.org\/10.3390\/genes16080954","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}